Description:

ODM derived from http://clinicaltrials.gov/ct2/show/NCT00334295?term=NCT00334295&rank=1

Link:
http://clinicaltrials.gov/ct2/show/NCT00334295?term=NCT00334295&rank=1
Keywords:
  1. 2/16/12 2/16/12 -
  2. 4/13/14 4/13/14 - Julian Varghese
  3. 8/10/14 8/10/14 - Martin Dugas
  4. 9/20/21 9/20/21 -
Uploaded on:

September 20, 2021

DOI:
To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00334295 Metastatic Endometrial Carcinoma

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
18 Years and older
Female Gender
Histologically confirmed, recurrent or metastatic endometrial carcinoma
Postmenopausal
Hormonreceptor positive tumor
Exclusion criteria
Pre-treatment with Fulvestrant
Previous endocrine therapy of the endometrial carcinoma
Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial